Tilray (TLRY) yesterday morning announced it has successfully imported medical cannabis into the United States from Canada in support of a new clinical trial. The study will test the efficacy of medical cannabis in treating patients with breast cancer who are suffering from taxane-induced peripheral neuropathy secondary to treatment with paclitaxel or docetaxel.

This clinical trial is the first human study testing the effectiveness of medical cannabis to treat TIPN, the company said.

"We're excited to support this groundbreaking, first-of-its-kind trial seeking to find a new treatment option for TIPN," says Philippe Lucas, Tilray's Vice President of Global Patient Research and Access.

"Tilray is committed to advancing cannabis research through its support of clinical trials around the world as we continue to enhance our understanding of the potential benefits of medical cannabis." Tilray shares closed Thursday up 8%, or $1.75, to $24.38.